

Europe Urological Cancer Drugs Market Report 2017

<https://marketpublishers.com/r/EC672889954EN.html>

Date: February 2017

Pages: 122

Price: US\$ 3,900.00 (Single User License)

ID: EC672889954EN

Abstracts

Notes:

Sales, means the sales volume of Urological Cancer Drugs

Revenue, means the sales value of Urological Cancer Drugs

This report studies sales (consumption) of Urological Cancer Drugs in Europe market, especially in Germany, France, UK, Russia, Italy, Spain and Benelux, focuses on top players in these countries, with sales, price, revenue and market share for each player in these Countries, covering

Novartis

Pfizer

Johnson & Johnson

AstraZeneca

Astellas

Bristol-Myers Squibb

Abbott Laboratories

Celgene Corporation

Dendreon Corporation

Ferring Pharmaceuticals

GlaxoSmithKline

Indevus Pharmaceuticals Inc

Ipsen

Roche Healthcare

Sanofi S.A.

Tolmar Inc

Market Segment by Countries, this report splits Europe into several key Countries, with sales (consumption), revenue, market share and growth rate of Urological Cancer Drugs in these countries, from 2011 to 2021 (forecast), like

Germany

France

UK

Russia

Italy

Spain

Benelux

Split by product type, with sales, revenue, price, market share and growth rate of each type, can be divided into

Xofigo (Radium Ra 223 Dichloride)

Jevtana (Cabazitaxel)

Inlyta (Axitinib)

Votrient (Pazopanib Hydrochloride)

Sutent (Sunitinib Malate)

Zytiga (Abiraterone Acetate)

Xtandi (Enzalutamide)

Opdivo (Nivolumab)

Provenge (Sipuleucel-T)

Split by application, this report focuses on sales, market share and growth rate of Urological Cancer Drugs in each application, can be divided into

Prostate Cancer

Bladder Cancer

Kidney Cancer

Testicular Cancer

Contents

Europe Urological Cancer Drugs Market Report 2017

1 UROLOGICAL CANCER DRUGS OVERVIEW

- 1.1 Product Overview and Scope of Urological Cancer Drugs
- 1.2 Classification of Urological Cancer Drugs
 - 1.2.1 Xofigo (Radium Ra 223 Dichloride)
 - 1.2.2 Jevtana (Cabazitaxel)
 - 1.2.3 Inlyta (Axitinib)
 - 1.2.4 Votrient (Pazopanib Hydrochloride)
 - 1.2.5 Sutent (Sunitinib Malate)
 - 1.2.6 Zytiga (Abiraterone Acetate)
 - 1.2.7 Xtandi (Enzalutamide)
 - 1.2.8 Opdivo (Nivolumab)
 - 1.2.9 Provenge (Sipuleucel-T)
- 1.3 Application of Urological Cancer Drugs
 - 1.3.1 Prostate Cancer
 - 1.3.2 Bladder Cancer
 - 1.3.3 Kidney Cancer
 - 1.3.4 Testicular Cancer
- 1.4 Urological Cancer Drugs Market by Countries
 - 1.4.1 Germany Status and Prospect (2012-2022)
 - 1.4.2 France Status and Prospect (2012-2022)
 - 1.4.3 UK Status and Prospect (2012-2022)
 - 1.4.4 Russia Status and Prospect (2012-2022)
 - 1.4.5 Italy Status and Prospect (2012-2022)
 - 1.4.6 Spain Status and Prospect (2012-2022)
 - 1.4.7 Benelux Status and Prospect (2012-2022)
- 1.5 Europe Market Size (Value and Volume) of Urological Cancer Drugs (2012-2022)
 - 1.5.1 Europe Urological Cancer Drugs Sales and Growth Rate (2012-2022)
 - 1.5.2 Europe Urological Cancer Drugs Revenue and Growth Rate (2012-2022)

2 EUROPE UROLOGICAL CANCER DRUGS BY MANUFACTURERS, TYPE AND APPLICATION

- 2.1 Europe Urological Cancer Drugs Market Competition by Manufacturers
 - 2.1.1 Europe Urological Cancer Drugs Sales and Market Share of Key Manufacturers

(2015 and 2016)

2.1.2 Europe Urological Cancer Drugs Revenue and Share by Manufacturers (2015 and 2016)

2.2 Europe Urological Cancer Drugs (Volume and Value) by Type

2.2.1 Europe Urological Cancer Drugs Sales and Market Share by Type (2012-2017)

2.2.2 Europe Urological Cancer Drugs Revenue and Market Share by Type (2012-2017)

2.3 Europe Urological Cancer Drugs (Volume and Value) by Countries

2.3.1 Europe Urological Cancer Drugs Sales and Market Share by Countries (2012-2017)

2.3.2 Europe Urological Cancer Drugs Revenue and Market Share by Countries (2012-2017)

2.4 Europe Urological Cancer Drugs (Volume) by Application

3 GERMANY UROLOGICAL CANCER DRUGS (VOLUME, VALUE AND SALES PRICE)

3.1 Germany Urological Cancer Drugs Sales and Value (2012-2017)

3.1.1 Germany Urological Cancer Drugs Sales and Growth Rate (2012-2017)

3.1.2 Germany Urological Cancer Drugs Revenue and Growth Rate (2012-2017)

3.1.3 Germany Urological Cancer Drugs Sales Price Trend (2012-2017)

3.2 Germany Urological Cancer Drugs Sales and Market Share by Manufacturers

3.3 Germany Urological Cancer Drugs Sales and Market Share by Type

3.4 Germany Urological Cancer Drugs Sales and Market Share by Application

4 FRANCE UROLOGICAL CANCER DRUGS (VOLUME, VALUE AND SALES PRICE)

4.1 France Urological Cancer Drugs Sales and Value (2012-2017)

4.1.1 France Urological Cancer Drugs Sales and Growth Rate (2012-2017)

4.1.2 France Urological Cancer Drugs Revenue and Growth Rate (2012-2017)

4.1.4 France Urological Cancer Drugs Sales Price Trend (2012-2017)

4.2 France Urological Cancer Drugs Sales and Market Share by Manufacturers

4.3 France Urological Cancer Drugs Sales and Market Share by Type

4.4 France Urological Cancer Drugs Sales and Market Share by Application

5 UK UROLOGICAL CANCER DRUGS (VOLUME, VALUE AND SALES PRICE)

5.1 UK Urological Cancer Drugs Sales and Value (2012-2017)

- 5.1.1 UK Urological Cancer Drugs Sales and Growth Rate (2012-2017)
- 5.1.2 UK Urological Cancer Drugs Revenue and Growth Rate (2012-2017)
- 5.1.5 UK Urological Cancer Drugs Sales Price Trend (2012-2017)
- 5.2 UK Urological Cancer Drugs Sales and Market Share by Manufacturers
- 5.3 UK Urological Cancer Drugs Sales and Market Share by Type
- 5.4 UK Urological Cancer Drugs Sales and Market Share by Application

6 RUSSIA UROLOGICAL CANCER DRUGS (VOLUME, VALUE AND SALES PRICE)

- 6.1 Russia Urological Cancer Drugs Sales and Value (2012-2017)
 - 6.1.1 Russia Urological Cancer Drugs Sales and Growth Rate (2012-2017)
 - 6.1.2 Russia Urological Cancer Drugs Revenue and Growth Rate (2012-2017)
 - 6.1.6 Russia Urological Cancer Drugs Sales Price Trend (2012-2017)
- 6.2 Russia Urological Cancer Drugs Sales and Market Share by Manufacturers
- 6.3 Russia Urological Cancer Drugs Sales and Market Share by Type
- 6.4 Russia Urological Cancer Drugs Sales and Market Share by Application

7 ITALY UROLOGICAL CANCER DRUGS (VOLUME, VALUE AND SALES PRICE)

- 7.1 Italy Urological Cancer Drugs Sales and Value (2012-2017)
 - 7.1.1 Italy Urological Cancer Drugs Sales and Growth Rate (2012-2017)
 - 7.1.2 Italy Urological Cancer Drugs Revenue and Growth Rate (2012-2017)
 - 7.1.7 Italy Urological Cancer Drugs Sales Price Trend (2012-2017)
- 7.2 Italy Urological Cancer Drugs Sales and Market Share by Manufacturers
- 7.3 Italy Urological Cancer Drugs Sales and Market Share by Type
- 7.4 Italy Urological Cancer Drugs Sales and Market Share by Application

8 SPAIN UROLOGICAL CANCER DRUGS (VOLUME, VALUE AND SALES PRICE)

- 8.1 Spain Urological Cancer Drugs Sales and Value (2012-2017)
 - 8.1.1 Spain Urological Cancer Drugs Sales and Growth Rate (2012-2017)
 - 8.1.2 Spain Urological Cancer Drugs Revenue and Growth Rate (2012-2017)
 - 8.1.8 Spain Urological Cancer Drugs Sales Price Trend (2012-2017)
- 8.2 Spain Urological Cancer Drugs Sales and Market Share by Manufacturers
- 8.3 Spain Urological Cancer Drugs Sales and Market Share by Type
- 8.4 Spain Urological Cancer Drugs Sales and Market Share by Application

9 BENELUX UROLOGICAL CANCER DRUGS (VOLUME, VALUE AND SALES PRICE)

- 9.1 Benelux Urological Cancer Drugs Sales and Value (2012-2017)
 - 9.1.1 Benelux Urological Cancer Drugs Sales and Growth Rate (2012-2017)
 - 9.1.2 Benelux Urological Cancer Drugs Revenue and Growth Rate (2012-2017)
 - 9.1.9 Benelux Urological Cancer Drugs Sales Price Trend (2012-2017)
- 9.2 Benelux Urological Cancer Drugs Sales and Market Share by Manufacturers
- 9.3 Benelux Urological Cancer Drugs Sales and Market Share by Type
- 9.4 Benelux Urological Cancer Drugs Sales and Market Share by Application

10 EUROPE UROLOGICAL CANCER DRUGS MANUFACTURERS ANALYSIS

10.1 Novartis

- 10.1.1 Company Basic Information, Manufacturing Base and Competitors
- 10.1.2 Urological Cancer Drugs Product Type, Application and Specification
 - 10.1.2.1 Xofigo (Radium Ra 223 Dichloride)
 - 10.1.2.2 Jevtana (Cabazitaxel)
- 10.1.3 Novartis Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
- 10.1.4 Main Business/Business Overview

10.2 Pfizer

- 10.2.1 Company Basic Information, Manufacturing Base and Competitors
- 10.2.2 Urological Cancer Drugs Product Type, Application and Specification
 - 10.2.2.1 Xofigo (Radium Ra 223 Dichloride)
 - 10.2.2.2 Jevtana (Cabazitaxel)
- 10.2.3 Pfizer Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
- 10.2.4 Main Business/Business Overview

10.3 Johnson & Johnson

- 10.3.1 Company Basic Information, Manufacturing Base and Competitors
- 10.3.2 Urological Cancer Drugs Product Type, Application and Specification
 - 10.3.2.1 Xofigo (Radium Ra 223 Dichloride)
 - 10.3.2.2 Jevtana (Cabazitaxel)
- 10.3.3 Johnson & Johnson Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
- 10.3.4 Main Business/Business Overview

10.4 AstraZeneca

- 10.4.1 Company Basic Information, Manufacturing Base and Competitors
- 10.4.2 Urological Cancer Drugs Product Type, Application and Specification
 - 10.4.2.1 Xofigo (Radium Ra 223 Dichloride)

- 10.4.2.2 Jevtana (Cabazitaxel)
- 10.4.3 AstraZeneca Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
- 10.4.4 Main Business/Business Overview
- 10.5 Astellas
 - 10.5.1 Company Basic Information, Manufacturing Base and Competitors
 - 10.5.2 Urological Cancer Drugs Product Type, Application and Specification
 - 10.5.2.1 Xofigo (Radium Ra 223 Dichloride)
 - 10.5.2.2 Jevtana (Cabazitaxel)
 - 10.5.3 Astellas Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
 - 10.5.4 Main Business/Business Overview
- 10.6 Bristol-Myers Squibb
 - 10.6.1 Company Basic Information, Manufacturing Base and Competitors
 - 10.6.2 Urological Cancer Drugs Product Type, Application and Specification
 - 10.6.2.1 Xofigo (Radium Ra 223 Dichloride)
 - 10.6.2.2 Jevtana (Cabazitaxel)
 - 10.6.3 Bristol-Myers Squibb Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
 - 10.6.4 Main Business/Business Overview
- 10.7 Abbott Laboratories
 - 10.7.1 Company Basic Information, Manufacturing Base and Competitors
 - 10.7.2 Urological Cancer Drugs Product Type, Application and Specification
 - 10.7.2.1 Xofigo (Radium Ra 223 Dichloride)
 - 10.7.2.2 Jevtana (Cabazitaxel)
 - 10.7.3 Abbott Laboratories Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
 - 10.7.4 Main Business/Business Overview
- 10.8 Celgene Corporation
 - 10.8.1 Company Basic Information, Manufacturing Base and Competitors
 - 10.8.2 Urological Cancer Drugs Product Type, Application and Specification
 - 10.8.2.1 Xofigo (Radium Ra 223 Dichloride)
 - 10.8.2.2 Jevtana (Cabazitaxel)
 - 10.8.3 Celgene Corporation Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
 - 10.8.4 Main Business/Business Overview
- 10.9 Dendreon Corporation
 - 10.9.1 Company Basic Information, Manufacturing Base and Competitors
 - 10.9.2 Urological Cancer Drugs Product Type, Application and Specification

- 10.9.2.1 Xofigo (Radium Ra 223 Dichloride)
- 10.9.2.2 Jevtana (Cabazitaxel)
- 10.9.3 Dendreon Corporation Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
- 10.9.4 Main Business/Business Overview
- 10.10 Ferring Pharmaceuticals
 - 10.10.1 Company Basic Information, Manufacturing Base and Competitors
 - 10.10.2 Urological Cancer Drugs Product Type, Application and Specification
 - 10.10.2.1 Xofigo (Radium Ra 223 Dichloride)
 - 10.10.2.2 Jevtana (Cabazitaxel)
 - 10.10.3 Ferring Pharmaceuticals Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
 - 10.10.4 Main Business/Business Overview
- 10.11 GlaxoSmithKline
- 10.12 Indevus Pharmaceuticals Inc
- 10.13 Ipsen
- 10.14 Roche Healthcare
- 10.15 Sanofi S.A.
- 10.16 Tolmar Inc

11 UROLOGICAL CANCER DRUGS MANUFACTURING COST ANALYSIS

- 11.1 Urological Cancer Drugs Key Raw Materials Analysis
 - 11.1.1 Key Raw Materials
 - 11.1.2 Price Trend of Key Raw Materials
 - 11.1.3 Key Suppliers of Raw Materials
 - 11.1.4 Market Concentration Rate of Raw Materials
- 11.2 Proportion of Manufacturing Cost Structure
 - 11.2.1 Raw Materials
 - 11.2.2 Labor Cost
 - 11.2.3 Manufacturing Expenses
- 11.3 Manufacturing Process Analysis of Urological Cancer Drugs

12 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

- 12.1 Urological Cancer Drugs Industrial Chain Analysis
- 12.2 Upstream Raw Materials Sourcing
- 12.3 Raw Materials Sources of Urological Cancer Drugs Major Manufacturers in 2015
- 12.4 Downstream Buyers

13 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

13.1 Marketing Channel

13.1.1 Direct Marketing

13.1.2 Indirect Marketing

13.1.3 Marketing Channel Development Trend

13.2 Market Positioning

13.2.1 Pricing Strategy

13.2.2 Brand Strategy

13.2.3 Target Client

13.3 Distributors/Traders List

14 EUROPE UROLOGICAL CANCER DRUGS MARKET FORECAST (2017-2022)

14.1 Germany Urological Cancer Drugs Sales Forecast (2017-2022)

14.2 France Urological Cancer Drugs Sales Forecast (2017-2022)

14.3 UK Urological Cancer Drugs Sales Forecast (2017-2022)

14.4 Russia Urological Cancer Drugs Sales Forecast (2017-2022)

14.5 Italy Urological Cancer Drugs Sales Forecast (2017-2022)

14.6 Spain Urological Cancer Drugs Sales Forecast (2017-2022)

14.7 Benelux Urological Cancer Drugs Sales Forecast (2017-2022)

14.8 Europe Urological Cancer Drugs Sales Forecast by Type (2017-2022)

14.9 Europe Urological Cancer Drugs Sales Forecast by Application (2017-2022)

15 RESEARCH FINDINGS AND CONCLUSION

16 APPENDIX

Methodology

Analyst Introduction

Data Source

The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Picture of Urological Cancer Drugs
Table Classification of Urological Cancer Drugs
Figure Europe Sales Market Share of Urological Cancer Drugs by Type in 2015
Figure Xofigo (Radium Ra 223 Dichloride) Picture
Figure Jevtana (Cabazitaxel) Picture
Figure Inlyta (Axitinib) Picture
Figure Votrient (Pazopanib Hydrochloride) Picture
Figure Sutent (Sunitinib Malate) Picture
Figure Zytiga (Abiraterone Acetate) Picture
Figure Xtandi (Enzalutamide) Picture
Figure Opdivo (Nivolumab) Picture
Figure Provenge (Sipuleucel-T) Picture
Table Application of Urological Cancer Drugs
Figure Europe Sales Market Share of Urological Cancer Drugs by Application in 2015
Figure Prostate Cancer Examples
Figure Bladder Cancer Examples
Figure Kidney Cancer Examples
Figure Testicular Cancer Examples
Figure Germany Urological Cancer Drugs Revenue and Growth Rate (2012-2022)
Figure France Urological Cancer Drugs Revenue and Growth Rate (2012-2022)
Figure UK Urological Cancer Drugs Revenue and Growth Rate (2012-2022)
Figure Russia Urological Cancer Drugs Revenue and Growth Rate (2012-2022)
Figure Italy Urological Cancer Drugs Revenue and Growth Rate (2012-2022)
Figure Spain Urological Cancer Drugs Revenue and Growth Rate (2012-2022)
Figure Benelux Urological Cancer Drugs Revenue and Growth Rate (2012-2022)
Figure Europe Urological Cancer Drugs Sales and Growth Rate (2012-2022)
Figure Europe Urological Cancer Drugs Revenue and Growth Rate (2012-2022)
Table Europe Urological Cancer Drugs Sales of Key Manufacturers (2015 and 2016)
Table Europe Urological Cancer Drugs Sales Share by Manufacturers (2015 and 2016)
Figure 2015 Urological Cancer Drugs Sales Share by Manufacturers
Figure 2016 Urological Cancer Drugs Sales Share by Manufacturers
Table Europe Urological Cancer Drugs Revenue by Manufacturers (2015 and 2016)
Table Europe Urological Cancer Drugs Revenue Share by Manufacturers (2015 and 2016)
Table 2015 Europe Urological Cancer Drugs Revenue Share by Manufacturers

Table 2016 Europe Urological Cancer Drugs Revenue Share by Manufacturers
Table Europe Urological Cancer Drugs Sales and Market Share by Type (2012-2017)
Table Europe Urological Cancer Drugs Sales Share by Type (2012-2017)
Figure Sales Market Share of Urological Cancer Drugs by Type (2012-2017)
Figure Europe Urological Cancer Drugs Sales Growth Rate by Type (2012-2017)
Table Europe Urological Cancer Drugs Revenue and Market Share by Type (2012-2017)
Table Europe Urological Cancer Drugs Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Urological Cancer Drugs by Type (2012-2017)
Figure Europe Urological Cancer Drugs Revenue Growth Rate by Type (2012-2017)
Table Europe Urological Cancer Drugs Sales and Market Share by Countries (2012-2017)
Table Europe Urological Cancer Drugs Sales Share by Countries (2012-2017)
Figure Sales Market Share of Urological Cancer Drugs by Countries (2012-2017)
Table Europe Urological Cancer Drugs Revenue and Market Share by Countries (2012-2017)
Table Europe Urological Cancer Drugs Revenue Share by Countries (2012-2017)
Figure Revenue Market Share of Urological Cancer Drugs by Countries (2012-2017)
Table Europe Urological Cancer Drugs Sales and Market Share by Application (2012-2017)
Table Europe Urological Cancer Drugs Sales Share by Application (2012-2017)
Figure Sales Market Share of Urological Cancer Drugs by Application (2012-2017)
Figure Germany Urological Cancer Drugs Sales and Growth Rate (2012-2017)
Figure Germany Urological Cancer Drugs Revenue and Growth Rate (2012-2017)
Figure Germany Urological Cancer Drugs Sales Price Trend (2012-2017)
Table Germany Urological Cancer Drugs Sales by Manufacturers (2015 and 2016)
Table Germany Urological Cancer Drugs Market Share by Manufacturers (2015 and 2016)
Table Germany Urological Cancer Drugs Sales by Type (2015 and 2016)
Table Germany Urological Cancer Drugs Market Share by Type (2015 and 2016)
Table Germany Urological Cancer Drugs Sales by Application (2015 and 2016)
Table Germany Urological Cancer Drugs Market Share by Application (2015 and 2016)
Figure France Urological Cancer Drugs Sales and Growth Rate (2012-2017)
Figure France Urological Cancer Drugs Revenue and Growth Rate (2012-2017)
Figure France Urological Cancer Drugs Sales Price Trend (2012-2017)
Table France Urological Cancer Drugs Sales by Manufacturers (2015 and 2016)
Table France Urological Cancer Drugs Market Share by Manufacturers (2015 and 2016)
Table France Urological Cancer Drugs Sales by Type (2015 and 2016)
Table France Urological Cancer Drugs Market Share by Type (2015 and 2016)

Table France Urological Cancer Drugs Sales by Application (2015 and 2016)
Table France Urological Cancer Drugs Market Share by Application (2015 and 2016)
Figure UK Urological Cancer Drugs Sales and Growth Rate (2012-2017)
Figure UK Urological Cancer Drugs Revenue and Growth Rate (2012-2017)
Figure UK Urological Cancer Drugs Sales Price Trend (2012-2017)
Table UK Urological Cancer Drugs Sales by Manufacturers (2015 and 2016)
Table UK Urological Cancer Drugs Market Share by Manufacturers (2015 and 2016)
Table UK Urological Cancer Drugs Sales by Type (2015 and 2016)
Table UK Urological Cancer Drugs Market Share by Type (2015 and 2016)
Table UK Urological Cancer Drugs Sales by Application (2015 and 2016)
Table UK Urological Cancer Drugs Market Share by Application (2015 and 2016)
Figure Russia Urological Cancer Drugs Sales and Growth Rate (2012-2017)
Figure Russia Urological Cancer Drugs Revenue and Growth Rate (2012-2017)
Figure Russia Urological Cancer Drugs Sales Price Trend (2012-2017)
Table Russia Urological Cancer Drugs Sales by Manufacturers (2015 and 2016)
Table Russia Urological Cancer Drugs Market Share by Manufacturers (2015 and 2016)
Table Russia Urological Cancer Drugs Sales by Type (2015 and 2016)
Table Russia Urological Cancer Drugs Market Share by Type (2015 and 2016)
Table Russia Urological Cancer Drugs Sales by Application (2015 and 2016)
Table Russia Urological Cancer Drugs Market Share by Application (2015 and 2016)
Figure Italy Urological Cancer Drugs Sales and Growth Rate (2012-2017)
Figure Italy Urological Cancer Drugs Revenue and Growth Rate (2012-2017)
Figure Italy Urological Cancer Drugs Sales Price Trend (2012-2017)
Table Italy Urological Cancer Drugs Sales by Manufacturers (2015 and 2016)
Table Italy Urological Cancer Drugs Market Share by Manufacturers (2015 and 2016)
Table Italy Urological Cancer Drugs Sales by Type (2015 and 2016)
Table Italy Urological Cancer Drugs Market Share by Type (2015 and 2016)
Table Italy Urological Cancer Drugs Sales by Application (2015 and 2016)
Table Italy Urological Cancer Drugs Market Share by Application (2015 and 2016)
Figure Spain Urological Cancer Drugs Sales and Growth Rate (2012-2017)
Figure Spain Urological Cancer Drugs Revenue and Growth Rate (2012-2017)
Figure Spain Urological Cancer Drugs Sales Price Trend (2012-2017)
Table Spain Urological Cancer Drugs Sales by Manufacturers (2015 and 2016)
Table Spain Urological Cancer Drugs Market Share by Manufacturers (2015 and 2016)
Table Spain Urological Cancer Drugs Sales by Type (2015 and 2016)
Table Spain Urological Cancer Drugs Market Share by Type (2015 and 2016)
Table Spain Urological Cancer Drugs Sales by Application (2015 and 2016)
Table Spain Urological Cancer Drugs Market Share by Application (2015 and 2016)
Figure Benelux Urological Cancer Drugs Sales and Growth Rate (2012-2017)

Figure Benelux Urological Cancer Drugs Revenue and Growth Rate (2012-2017)

Figure Benelux Urological Cancer Drugs Sales Price Trend (2012-2017)

Table Benelux Urological Cancer Drugs Sales by Manufacturers (2015 and 2016)

Table Benelux Urological Cancer Drugs Market Share by Manufacturers (2015 and 2016)

Table Benelux Urological Cancer Drugs Sales by Type (2015 and 2016)

Table Benelux Urological Cancer Drugs Market Share by Type (2015 and 2016)

Table Benelux Urological Cancer Drugs Sales by Application (2015 and 2016)

Table Benelux Urological Cancer Drugs Market Share by Application (2015 and 2016)

Table Urological Cancer Drugs Basic Information List

Table Novartis Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

Figure Novartis Urological Cancer Drugs Sales Market Share (2012-2017)

Table Pfizer Basic Information List

Table Pfizer Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

Table Pfizer Urological Cancer Drugs Sales Market Share (2012-2017)

Table Johnson & Johnson Basic Information List

Table Johnson & Johnson Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

Table Johnson & Johnson Urological Cancer Drugs Sales Market Share (2012-2017)

Table AstraZeneca Basic Information List

Table AstraZeneca Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

Table AstraZeneca Urological Cancer Drugs Sales Market Share (2012-2017)

Table Astellas Basic Information List

Table Astellas Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

Table Astellas Urological Cancer Drugs Sales Market Share (2012-2017)

Table Bristol-Myers Squibb Basic Information List

Table Bristol-Myers Squibb Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

Table Bristol-Myers Squibb Urological Cancer Drugs Sales Market Share (2012-2017)

Table Abbott Laboratories Basic Information List

Table Abbott Laboratories Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

Table Abbott Laboratories Urological Cancer Drugs Sales Market Share (2012-2017)

Table Celgene Corporation Basic Information List

Table Celgene Corporation Urological Cancer Drugs Sales, Revenue, Price and Gross

Margin (2012-2017)

Table Celgene Corporation Urological Cancer Drugs Sales Market Share (2012-2017)

Table Dendreon Corporation Basic Information List

Table Dendreon Corporation Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

Table Dendreon Corporation Urological Cancer Drugs Sales Market Share (2012-2017)

Table Ferring Pharmaceuticals Basic Information List

Table Ferring Pharmaceuticals Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

Table Ferring Pharmaceuticals Urological Cancer Drugs Sales Market Share (2012-2017)

Table GlaxoSmithKline Basic Information List

Table Indevus Pharmaceuticals Inc Basic Information List

Table Ipsen Basic Information List

Table Roche Healthcare Basic Information List

Table Sanofi S.A. Basic Information List

Table Tolmar Inc Basic Information List

Table Production Base and Market Concentration Rate of Raw Material

Figure Price Trend of Key Raw Materials

Table Key Suppliers of Raw Materials

Figure Manufacturing Cost Structure of Urological Cancer Drugs

Figure Manufacturing Process Analysis of Urological Cancer Drugs

Figure Urological Cancer Drugs Industrial Chain Analysis

Table Raw Materials Sources of Urological Cancer Drugs Major Manufacturers in 2015

Table Major Buyers of Urological Cancer Drugs

Table Distributors/Traders List

Figure Germany Urological Cancer Drugs Sales and Growth Rate Forecast (2017-2022)

Figure Germany Urological Cancer Drugs Revenue and Growth Rate Forecast (2017-2022)

Figure France Urological Cancer Drugs Sales and Growth Rate Forecast (2017-2022)

Figure France Urological Cancer Drugs Revenue and Growth Rate Forecast (2017-2022)

Figure UK Urological Cancer Drugs Sales and Growth Rate Forecast (2017-2022)

Figure UK Urological Cancer Drugs Revenue and Growth Rate Forecast (2017-2022)

Figure Russia Urological Cancer Drugs Sales and Growth Rate Forecast (2017-2022)

Figure Russia Urological Cancer Drugs Revenue and Growth Rate Forecast (2017-2022)

Figure Italy Urological Cancer Drugs Sales and Growth Rate Forecast (2017-2022)

Figure Italy Urological Cancer Drugs Revenue and Growth Rate Forecast (2017-2022)

Figure Spain Urological Cancer Drugs Sales and Growth Rate Forecast (2017-2022)

Figure Spain Urological Cancer Drugs Revenue and Growth Rate Forecast (2017-2022)

Figure Benelux Urological Cancer Drugs Sales and Growth Rate Forecast (2017-2022)

Figure Benelux Urological Cancer Drugs Revenue and Growth Rate Forecast
(2017-2022)

Table Europe Urological Cancer Drugs Sales Forecast by Type (2017-2022)

Table Europe Urological Cancer Drugs Sales Forecast by Application (2017-2022)

I would like to order

Product name: Europe Urological Cancer Drugs Market Report 2017

Product link: <https://marketpublishers.com/r/EC672889954EN.html>

Price: US\$ 3,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/EC672889954EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970